EVENTS · MRNA
PEERS
EARNINGS
Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
No company news, with Biotechnology higher as a group and Rhythm Pharmaceuticals and Viridian Therapeutics also up
| Series | 1W | 1M |
|---|---|---|
| MRNA | +20.6% | +37.8% |
| Peers | +1.3% | +4.6% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 99 | 100 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q2 FY2026 | −2.12 | −1.97 | +7.28% | −5.35% |
| Q1 FY2026 | −4.04 | −3.40 | +15.85% | +2.96% |
| Q4 FY2025 | −2.70 | −2.11 | +21.72% | +9.52% |
| Q3 FY2025 | −2.15 | −0.51 | +76.27% | +4.16% |
| Series | 1W | 1M |
|---|---|---|
| MRNA | +20.6% | +37.8% |
| Peers | +1.3% | +4.6% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 99 | 100 |
